 AstraZenecas stock dipped 5.8 in August, the biggest monthly fall in 2022, raising the question whether it is a good time to buy the otherwise high-performing stock on dip. Factors like relatively better performance by healthcare stocks in the current sluggish economy and markets, the companys geographical diversification, strong pricing power, and healthy financials work in its favor. 